PMID- 20708392
OWN - NLM
STAT- MEDLINE
DCOM- 20120709
LR  - 20171116
IS  - 1590-3729 (Electronic)
IS  - 0939-4753 (Linking)
VI  - 22
IP  - 3
DP  - 2012 Mar
TI  - Elevated advanced oxidation protein products (AOPPs) indicate metabolic risk in 
      severely obese children.
PG  - 237-43
LID - 10.1016/j.numecd.2010.06.002 [doi]
AB  - BACKGROUND AND AIMS: The assessment of oxidative stress may aid in the 
      identification of subsequent metabolic risk in obese children. The objective of 
      this study was to determine whether the plasma level of advanced oxidation 
      protein products, analyzed with a recently proposed modified assay that involves 
      a delipidation step (mAOPPs), was related to metabolic risk factors (MRFs) in 
      severely obese children. METHODS AND RESULTS: The plasma levels of mAOPPs were 
      determined by spectrophotometry in 54 severely obese and 44 healthy children. We 
      also measured lipid peroxidation biomarkers (thiobarbituric acid-reactive 
      substances, malondialdehyde, and 8-isoprotane F(2alpha)) and sulfhydryl groups, a 
      marker of antioxidant defense. Protein oxidation and lipid peroxidation markers 
      were higher and sulfhydryl levels were lower in obese children compared with 
      controls. Taking metabolic risk into account, obese children were subdivided 
      according to the cutoff point (53.2 mumol/L) obtained for their mAOPPs values from 
      the ROC curve. Anthropometric measures and the existence of hypertension did not 
      differ between groups. The presence of dyslipidemia and insulin resistance was 
      significantly higher in the group with higher mAOPPs levels. The highest levels 
      of mAOPPs were found in the children with >/=3 MRFs. The level of mAOPPs was 
      positively correlated with triglycerides and negatively correlated with 
      high-density lipoprotein cholesterol. There was no correlation of this marker of 
      protein oxidation with biomarkers of lipid peroxidation. CONCLUSION: The 
      determination of mAOPPs in delipidated plasma is an easy way to evaluate protein 
      oxidation. It may be useful in severely obese children for better cardiovascular 
      risk assessment.
CI  - Copyright A(c) 2010 Elsevier B.V. All rights reserved.
FAU - Codoner-Franch, P
AU  - Codoner-Franch P
AD  - Department of Pediatrics, Dr. Peset University Hospital, Avda Gaspar Aguilar 90, 
      46017 Valencia, Spain. pilar.codoner@uv.es
FAU - Tavarez-Alonso, S
AU  - Tavarez-Alonso S
FAU - Murria-Estal, R
AU  - Murria-Estal R
FAU - Tortajada-Girbes, M
AU  - Tortajada-Girbes M
FAU - Simo-Jorda, R
AU  - Simo-Jorda R
FAU - Alonso-Iglesias, E
AU  - Alonso-Iglesias E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100812
PL  - Netherlands
TA  - Nutr Metab Cardiovasc Dis
JT  - Nutrition, metabolism, and cardiovascular diseases : NMCD
JID - 9111474
RN  - 0 (Biomarkers)
RN  - 0 (Lipids)
RN  - 0 (Proteins)
RN  - 0 (Sulfhydryl Compounds)
RN  - 0 (Thiobarbituric Acid Reactive Substances)
RN  - 27415-26-5 (8-epi-prostaglandin F2alpha)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - B7IN85G1HY (Dinoprost)
SB  - IM
MH  - Adolescent
MH  - Age of Onset
MH  - Biomarkers/blood
MH  - Chi-Square Distribution
MH  - Child
MH  - Dinoprost/analogs & derivatives/blood
MH  - Dyslipidemias/epidemiology
MH  - Female
MH  - Humans
MH  - Hypertension/epidemiology
MH  - Insulin Resistance
MH  - Linear Models
MH  - Lipid Peroxidation
MH  - Lipids/blood
MH  - Male
MH  - Malondialdehyde/blood
MH  - Metabolic Syndrome/*blood/epidemiology/physiopathology
MH  - Obesity/*blood/epidemiology/physiopathology
MH  - Oxidation-Reduction
MH  - *Oxidative Stress
MH  - Proteins/*metabolism
MH  - Risk Assessment
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Spain/epidemiology
MH  - Spectrophotometry
MH  - Sulfhydryl Compounds/blood
MH  - Thiobarbituric Acid Reactive Substances/metabolism
MH  - Up-Regulation
EDAT- 2010/08/17 06:00
MHDA- 2012/07/10 06:00
CRDT- 2010/08/17 06:00
PHST- 2010/01/21 00:00 [received]
PHST- 2010/04/25 00:00 [revised]
PHST- 2010/06/03 00:00 [accepted]
PHST- 2010/08/17 06:00 [entrez]
PHST- 2010/08/17 06:00 [pubmed]
PHST- 2012/07/10 06:00 [medline]
AID - S0939-4753(10)00131-6 [pii]
AID - 10.1016/j.numecd.2010.06.002 [doi]
PST - ppublish
SO  - Nutr Metab Cardiovasc Dis. 2012 Mar;22(3):237-43. doi: 
      10.1016/j.numecd.2010.06.002. Epub 2010 Aug 12.